The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 146 affiliates and more than 47,700 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.
Our businesses
Contact Details
Private Bag X3032
Randburg
2125
South Africa
Phone +27/11/348 2400
Fax +27/11/886 3205
Boehringer Ingelheim has a 60-year history in Portugal and, despite challenges in terms of market access and reimbursement delays, remains fully committed to providing innovative healthcare solutions in the country.…
Dr Anthony Y. Lauw, GM & Head of Human Pharma Northwest Africa at Boehringer Ingelheim, explains the operations of a cluster that has typically worked with local partners, but that…
Malaysian national Jonathan Chin culminated his 20+-year career at Boehringer Ingelheim and became GM of the firm’s Hong Kong and Macau affiliate in 2022. He explains his career path through…
Boehringer Ingelheim’s Marianne Abou Elkheir, General Manager and Head of Human Pharma for Levant, Iraq and North-East Africa (LINEA) and Sub-Saharan Africa (SSA), walks us through her career trajectory and…
Boehringer Ingelheim’s managing director for South America, Dirk van Niekerk, provides an overview of the healthcare climate in South America, the challenges tied to political and economic instability, future opportunities…
Boehringer Ingelheim’s Nicolas Dumoulin outlines Denmark’s relevance to the German family-owned company, including the strong uptake of its diabetes and COPD medications in the country and its host of research…
Boehringer Ingelheim’s Regional Managing Director and Head of Human Pharma in the Middle East, Turkey, and Africa (‘META’) Mohammed Al-Tawil reflects on more than two decades of his career with…
Evren Özlü, General Manager of Turkey and Sub-Saharan Africa at Boehringer Ingelheim, discusses the company’s double-digit growth in the last year, and its leading position as one of the fastest…
Francesco Banchi, general manager of Boehringer Ingelheim Hungary, elaborates on the successful development of the affiliate in recent years, making progress in new product reimbursement. As an experienced leader in…
Boehringer Ingelheim veteran executive Felix Gutsche shares the first impressions of the China market since he joined in January 2019; the strategic significance of the market as one of the…
Dr Armin Wiesler, general manager and head of Human Pharma at Boehringer Ingelheim (Thai) Ltd., explores how the affiliate has managed to achieve market-leading growth rates and addressed the challenges…
Andrea Sambatti is the general manager of Boehringer Ingelheim (BI) Sweden and is a member of the board of directors for LIF. Sambatti discusses how Sweden is a testbed for…
Timmo Andersen, general manager of Boehringer Ingelheim in Spain, explains how the affiliate has managed to achieve market-leading growth rates, the challenges and opportunities of the Spanish pharma market, and…
Philipp von Lattorff, country managing director of Boehringer Ingelheim’s Regional Centre Vienna (RCV) discusses the current mandate of the center and the dynamic performance of its 33 members, as well…
Javier Castro of Boehringer Ingelheim (BI) Colombia has been mandated to integrate Sanofi’s animal healthcare business into BI’s operation and prepare the Colombian affiliate for the coming changes in the…
Jorge Wagner, President Director at Boehringer Ingelheim Indonesia, explains the importance of innovation within the universal healthcare coverage program that is being implemented in Indonesia. He also illustrates how the…
Dimitris Anagnostakis is emblematic of Boehringer Ingelheim’s corporate values as evidenced by his 26-year loyalty to the company promoting the advancement of innovation. As the General Manager spearheading the only…
Boehringer Ingelheim’s (BI) country managing director in South East Asia and South Korea (SEASK), Gerrard McKenna characterizes the recent changes within the family-owned business as “evolutionary” in nature, while highlighting…
Egypt is at the ‘golden stage’ for investment, claims Boehringer Ingelheim country head Mohamed El-Sahhar, who explains how the company is expanding their organization in Egypt ahead of an expansion…
Dr. Anna Maria Porrini, President of Boehringer Ingelheim Italy shares her vision for the company, how she intends to achieve it and where she sees opportunities for the company’s success…
The General Manager of Boehringer Ingelheim South Africa talks about changes that are required to the healthcare system, with far more government/private partnerships, helping to unlock the country´s potential, why…
Sirilak Suteekul explains the organization’s success in Thailand over the last couple of years, Thailand’s untapped potential as a regional center in Southeast Asia and how innovation adds value to…
Javier Castro came from Boehringer Ingelheim’s headquarters to run the Peruvian affiliate in January 2015, bringing with him a wealth of experience necessary to take the company to the next…
Boehringer Ingelheim is turning 130 in 2015. Miguel Salazar, president and country managing director for Mexico, explains how he is steering the company to bypass the currents of the ever-changing…
The general manager of BI Algeria discusses how Algeria could benefit from participating in international clinical trials and describes how his company is adapting its offering to mirror the changing health…
Karim El-Alaoui Mustapha, Managing Diretor of Boehringer Ingelheim, MENA, talks about the company’s two-fold strategy in attracting, and maintaining, talent; what have been the key successes since it’s founding; and…
There seems to be quite a hype around the Nordic region at the moment. How do you explain this phenomenon? I think that the Nordic region – the “quiet North”…
After 10 years of working with MSD, one of the top pharmaceutical companies in the world, what brought you here to Boehringer Ingelheim? Two key things brought me to this…
Dr. Edwards, you have been both a lecturer and a researcher. What made you ‘come over to the dark side’ and become a manager? I do not find it to…
What is the presence of Boehringer Ingelheim (BI) in Southeast Asia? In 2009, Boehringer Ingelheim decided to establish a regional operating unit for its human pharmaceutical division (prescription and OTC…
Austria has always been a strategic market for the group: it has played a key role in Boehringer Ingelheim’s success story, as this is where the company established its first…
Can you illustrate to our readers the company’s main milestones and key achievements since you took the reins four years ago? In the last years we have experienced a period…
Mr. Pfannenschmidt, you have been working for Boehringer Ingelheim for three decades, outlasting several company chairman and witnessing the birth and evolution of the corporate vision “Value through Innovation”. Before…
The main distinctive point of Boehringer Ingelheim Italy within the group is its business structure, which relies on three different units: Boehringer Ingelheim Spa, Bidachem and Istituto de Angeli. Could…
While already having worked for Boehringer Ingelheim for quite some time, the end of 2010 marked the completion of your first full year as general manager of this Dutch affiliate.…
You came to Boehringer Ingelheim in 2009 – what are some of the most exciting milestones and achievements you have presided over during this time? Looking back on almost three…
You arrived to the position of Boehringer Ingelheim Mexico’s General Director in 2010, what are some of the most exciting milestones and achievements you have presided over during this time?…
What have been Boehringer Ingelheim’s major milestones and achievements since your establishment in Chile? Chile, in the regional context, represents a very important market with a solid evolution in terms…
Looking at Boehringer Ingelheim (BI) in Hungary, at first glance we see a company with a presence of already 20 years, which basically means an entry into this market right…
If we take a look back at Boehringer Ingelheim’s dynamic growth path in the Romanian market, we see an evolution from a one-man show in the 1990s to a present…
You have been with Boehringer Ingelheim since the early days of your career in 1994. In the pharmaceutical sector, managers seem to jump from company to company quite often—but you…
Before moving into the company’s strategy, can you give our readers an idea of what role Boehringer Ingelheim India plays within the Group’s worldwide operations? Within the Boehringer Ingelheim Group,…
There is a lot of change occurring in the French pharmaceutical industry at the moment and this is no different for Boehringer Ingelheim. Just last September you moved into these…
After 20 years experience with Boehringer Ingelheim, what would you say are the main specificities of the Indonesian pharmaceutical industry? Indonesia differs some what from other Asian countries, starting from…
The country president of Novartis South Africa reveals how Novartis has recently moved to new premises, demonstrating a clear commitment to continue investing in the country; why South Africa…
The managing director at Adcock Ingram Critical Care reveals the company’s unique business model. As a long-established division within Adcock Ingram, Critical Care operates with relative independence. What is the relationship…
The head of operations of Hetero South Africa talks about the need for a more efficient regulatory system with a fast track process for essential molecules, and how Hetero is…
The CEO of Ascendis Health talks about their business model, being a long-term investment company that brings together healthy businesses in the healthcare industry, and how the diversification of their product…
Merck’s managing director for South Africa and general manager for Southeast Africa reveals why the company takes a long-term perspective when investing in African countries, helping to shape healthcare systems,…
The general manager of Novagen Pharma reveals how they are the second largest supplier of ARVs within the private South African market, how there is much room for the generics…
The country manager and Global Established Products Business Lead at Pfizer South Africa reveals how the private sector is committed to expanding healthcare for South Africans, why her ambition is…
The country manager of Dr. Reddy´s South Africa explains that while the perception of the quality of generics has improved in South Africa, there is still a long way to…
The CEO of NAPM reveals how the main challenge facing his members is the length of time needed to register a generic product, taking up to four years and acting…
Focus Reports is back in South Africa as part of a second set of reports on the BRICS. What would you say are the main changes in the market since…
South Africa is at the moment one of the world’s most exciting and dynamic markets at the moment as Mr. Omar Ehsan was telling us, the most exciting market he…
Could you introduce to our readers MC Pharma’s business model in the South African market as well as the main milestones in the company’s development over the recent years? MC…
See our Cookie Privacy Policy Here
